Medline Inc. (MDLN) fair value analysis
Nasdaq · Updated 2026-10-19
MDLN price how computed
Valuation status
Awaiting full valuationMDLN's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once MDLN's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $35.96
- Sector
- Healthcare
- 12-month range
- $31.64–$49.99
- Market cap
- $48.4B
- From 52-week high
- -28.1%
- Shares outstanding
- 1.35B
- Rank in Healthcare by quality score
- #211 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Medline Industries is a healthcare company that manufactures and distributes medical supplies, equipment, and solutions used in hospitals, clinics, long-term care facilities, and other healthcare settings. The company operates globally, serving customers across North America, Europe, Asia, and other international markets.
MDLN currently ranks #211 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $48.4B
- P/E (trailing)
- 24x
- Revenue (TTM)
- $29.9B
- Net margin
- 2.3%
- EPS (TTM)
- $1.49
- Gross margin
- 28.8%
- Debt / equity
- 1.09
- Shares outstanding
- 1.35B
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Stable
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 69 · neutral
- 50-day average
- $34.69
- 200-day average
- $40.02
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-04 (pre-market)
- Last 4 quarters vs consensus
- 4 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+56.7%)
2026-03 ▲ beat (+13.8%)
2025-12 ▲ beat (+58.3%)
2025-09 ▲ beat
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 23 buy · 4 hold · 0 sell (27 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $44.4
- Target vs last price
- +23.5%
What our data shows for MDLN
- Our model validated 1 trailing price-to-earnings windows for MDLN, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $31.64–$49.99.
- The 14-day relative strength index sits at a neutral 69.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- MDLN's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the MDLN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for MDLN show a shift this week as the Relative Strength Index moved from overbought territory into neutral zone. The current valuation verdict for this healthcare sector company remains awaiting full valuation. This change in the RSI zone suggests a moderation in the stock's recent momentum.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for MDLN in the Healthcare sector show two significant shifts this week. The 50/200-day trend state transitioned from none to mixed, while the Relative Strength Index zone moved from neutral to overbought. The current valuation verdict remains awaiting full valuation.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is MDLN stock undervalued?
MDLN's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is MDLN's TickrTrends verdict?
MDLN is currently marked 'Awaiting full valuation' - a verdict publishes automatically once MDLN's own trailing P/E history validates under our standards.
How does MDLN compare to other Healthcare stocks?
MDLN ranks #211 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is MDLN overbought or oversold?
MDLN's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does MDLN report earnings next?
MDLN's next earnings report is scheduled for 2026-11-04 (pre-market), per the published earnings calendar.
Does MDLN usually beat earnings estimates?
Over its last 4 reported quarters MDLN beat the consensus estimate 4 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about MDLN?
Of 27 analysts covering MDLN, 23 rate it a buy, 4 a hold and 0 a sell - buy-leaning, with a consensus price target of $44.4 (+23.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.